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Introduction:Fluoroquinolones are potent inhibitors of bacterial topoisomerase II. They can also 
inhibit eukaryotic topoisomerase, and may confer antitumoral properties.  
Method: In this study the antitumoral  activity of a new series of N-substituted piperazinyl- 
fluoroquinolones against a panel of human tumor cell lines was determined by MTT assays. 
Results: Among the tested compounds N-[2- (5-bromo-2-thienyl)-2-oxoethyl ] (C1,N1,E1), N-[ 2- 
(5-bromo-2-thienyl)-2-(hydroxyimino) ethyl]( C2,N2,E2) and N-[2-(5-bromo-2-thienyl)-2-
(phenylmethoxyimino) ethyl] (C3,N3,E3) piperazinyl quinolones  exhibited the most cytotoxic 
activities (mean IC50s = 2.5 to 3 µg/ml), comparable to that of the Etoposide (mean IC50= 
1.7µg/ml). Replacement of the 5- bromo-2-thienyl with 4- fluorophenyl or 2,6- difluorophenyl rings 
leads to variable inhibition activity.  The quinolone activity was enhanced by the presence of a 
chlorine and two fluorine atoms at the benzyl and phenyl groups, especially against ACHN renal 
adenocarcinoma cell line.  
Conclusion: These data suggest that these series of quinolones provide good models for the further 
design of potent antitumor compounds.  
Key words: Cytotoxicity, Fluoroquinolone, MTT- assay, Etoposide 
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